Comparative Pharmacology
Head-to-head clinical analysis: ISENTRESS HD versus JULUCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISENTRESS HD versus JULUCA.
ISENTRESS HD vs JULUCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Integrase strand transfer inhibitor (INSTI). Inhibits the catalytic activity of HIV-1 integrase, preventing integration of viral DNA into host genome.
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that inhibits the catalytic activity of HIV-1 integrase, preventing integration of viral DNA into host chromosomal DNA. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase via incorporation into viral DNA, causing chain termination.
600 mg orally twice daily, with or without food.
One tablet orally once daily, each tablet containing dolutegravir 50 mg and rilpivirine 25 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12.9 hours in adults, supporting twice-daily dosing. Prolonged in hepatic impairment.
Dolutegravir: ~14 hours (terminal; supports once-daily dosing). Lamivudine: ~13-19 hours (terminal; supports once-daily dosing; prolonged in renal impairment).
Primarily hepatic metabolism via UGT1A1 with glucuronidation; 51% excreted in feces (mainly as parent drug) and 32% in urine (mostly as metabolites).
Dolutegravir: 64% fecal (as unchanged drug), 32% renal (as glucuronide conjugate); <1% unchanged in urine. Lamivudine: 70% renal (as unchanged drug) via glomerular filtration and active tubular secretion; 5-10% as trans-sulfoxide metabolite.
Category C
Category C
HIV Integrase Inhibitor
HIV Integrase Inhibitor / NNRTI Combination